Myriad Genetics, Inc. (NASDAQ:MYGN) has declined 37.47% since June 13, 2016 and is downtrending. Regardless, closing prices are a useful tool that investors use to quantify changes in stock prices over time. Since February 22, …
Mr. R. Bryan Riggsbee is Chief Financial Officer and Treasurer of the Company. Mr. Riggsbee previously served 10 years with Laboratory Corporation of America (LabCorp) where his most recent position was as Senior Vice President of …
They now have a Dollars 25 price target on the stock. About 65,449 shares traded. (MYGN)'s stock rose 13.21%. It has underperformed by 54.17% the S&P500. It increased, as 31 investors sold Myriad Genetics, Inc. shares while 66 …
The sales growth rate for a stock is a measure of how the stock's sales per share ... Barclays Capital downgraded the shares of MYGN in report on Wednesday, …
(NASDAQ:MYGN) or 88,207 shares. There are many hard issues between ... The …
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through two segments: Diagnostics and Other. The Diagnostics segment engages in the provision of testing …
Inc. (MYGN) Our final stock for today is MYGN, which is more than 8% higher at $34.02, after Wells Fargo elevated the stock's rating to "outperform" from "market perform." Myriad Genetics, Inc. may be benefiting from short-covering …
Creative Planning now owns 6,371 shares of the company's stock worth $122,000 after buying an additional 671 shares during the period. They expect $0.26 earnings per share, down 27.78% or $0.10 from last year's $0.36 per share. …
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized ... Register now to create …